Hong Kong Stock Moves: Jinhai Medical Tech Surges Over 6% on Strong Minimally Invasive Surgery Device Market Growth

Stock News08-03

Jinhai Medical Tech (02225) shares climbed more than 6%, last trading up 5.63% at HKD 3.845, with turnover reaching HKD 10.4177 million. According to a report by MordorIntelligence, the minimally invasive surgery device market is expanding rapidly as industry players adapt to evolving clinical standards and patient needs.

China's minimally invasive surgery device market is among the fastest-growing globally, driven by the modernization of healthcare systems, an aging population, and the adoption of advanced technologies such as robotics, AI-assisted imaging, and minimally invasive surgical tools. The report also notes that China's minimally invasive surgery device industry is projected to reach a market size of USD 1.71 billion in 2025, growing to USD 2.68 billion by 2030, reflecting a compound annual growth rate of 9.45%.

Notably, Jinhai Medical Tech has achieved several significant breakthroughs in endoscopic technology research and development in recent years, covering a range of innovative products from 4K ultra-high-definition endoscopic systems, 3D and glasses-free 3D image processing systems, to 4K fluorescence and future multispectral ultra-high-definition endoscopic systems. Among these, the company's 4K 3D glasses-free fluorescence endoscopic camera system has secured a registration certificate for 4K 3D fluorescence endoscopes, positioning it as one of the leaders in the domestic high-end medical equipment sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment